top of page

LATEST SIGNALS
EXPLORE
Intelligence on the forces shaping federal health market dynamics
Resources
Search


The Prenatal Diagnostic Opportunity in VA and IHS
Bottom Line: Manufacturers of prenatal diagnostics who look at the VA and the IHS see two agencies with almost no internal maternity footprint and conclude there is nothing to sell into. The opposite is true. Both agencies deliver maternity care through community providers - clinicians manufacturers are frequently already calling on — which means the volume is not absent, it is unrecognized. The work is in identifying it and getting paid correctly for it. For manufacturers of


The DoD BAP Has (Finally) Convened
Bottom Line: The BAP cleared a massive volume of previously stalled DoD P&T Committee decisions. To protect market share and prevent access disruptions, manufacturers must act now. In late June 2026, the Department of Defense (DoD) Uniform Formulary Beneficiary Advisory Panel (BAP) held a public meeting that ended all Defense Health Agency (DHA) delays on final drug placement. The BAP systematically reviewed decisions from the eight previous Pharmacy and Therapeutics (P&T) Co


Leveraging FSS Sales as Strategic Evidence
Bottom Line Recognizing federal sales patterns as real-world evidence gives manufacturers the clinical validation private payers can use to justify coverage decisions. Pharmaceutical and medical device manufacturers that treat the execution of their Federal Supply Schedule (FSS) as the finish line of a sales journey rather than the starting point of a much more valuable evidence cycle miss a critical opportunity. When a manufacturer views its FSS sales solely through a transa


Modern DHA Field Force Alignment
Bottom Line: The Defense Health Agency’s unified network model requires manufacturers to align sales force structures to properly leverage local clinical utilization into regional data for network-wide product adoption across the military health infrastructure As the Defense Health Agency (DHA) combined its 20+ regional markets into 9 Defense Health Networks, it effectively rendered traditional commercial sales maps obsolete for this arena. Pharmaceutical and medical device m


Why Strategic Federal Access Precision Outperforms Scale
Bottom Line: Maximizing returns in the federal segment requires a pivot toward a model of high-precision strategic intervention that protects operational focus while providing the technical depth necessary to secure a durable competitive advantage. The Department of Veterans Affairs (VA), the Department of Defense (DoD), and the Indian Health Service (IHS) do not behave like traditional payers; they are integrated health systems that serve as both the payer and the provider.


Autonomous Tribal Health Networks
Bottom Line: Future market access in IHS depends on implementation of a sovereign account model that recognizes Tribal nations as high-agility delivery networks prioritizing clinical autonomy, cultural integration, and long-term medical self-sufficiency. For medical device and pharmaceutical manufacturers, the Indian Health Service (IHS) has historically been approached as a traditional federal payer similar to the Veterans Health Administration (VHA) or Defense Health Agency


DHA 2026 Readiness Mandate Impact on Manufacturer Value Positioning
Bottom Line By pivoting its 2025–2030 Strategic Plan toward a high-velocity functional mandate, the DHA is prioritizing mission-availability. Manufacturers must take this moment to evaluate current messaging and recalibrate their own messaging to show a direct reduction in warfighter downtime. The Defense Health Agency (DHA) is currently navigating a fundamental structural evolution between its established 2025–2030 Strategic Plan and a new set of performance-driven mandates


Aligning Clinical Value with PACT Act Operational Priorities
Bottom Line: The PACT Act significantly scaled the VHA’s care mission. Manufacturers succeed by aligning their clinical data with the system's operational goal of providing efficient, high-volume Veteran care. The PACT Act of 2022 represents the largest expansion in VA beneficiaries in a generation, fundamentally altering the VHA’s scope of responsibilities and its operational priorities. With millions of new Veterans now eligible for care, the health system is managing a sig


2016 Called, and It Wants Its VA Strategy Back
Bottom Line The 2026 VA RISE reorganization marginalizes the legacy site-by-site adoption approach, rendering local facility-level relationships insufficient and requiring a pivot toward an enterprise-aligned value strategy. The Department of Veterans Affairs (VA) is currently executing its most significant structural transformation in three decades: the Restructure for Impact and Sustainability Effort (RISE). By consolidating 18 Veterans Integrated Service Networks (VISNs) i
Get insights, expert perspectives, and emerging trends
bottom of page